Skip to main content

Table 1 Socio-demographic, co-morbidities, clinical characteristics, prescribed therapies and outcome of SARS-CoV-2-infected patients

From: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study

Characteristic

All patients

n = 288 (%)

Patients treated only with mAbs n = 94

Patients treated only with antivirals n = 171

Patients treated with both mAbs and antivirals

n = 23

Gender n (%)

 Male

151 (52.4%)

50 (53.2%)

87 (50.9%)

14 (60.9%)

 Female

137 (47.6%)

44 (46.8%)

84 (49.1%)

9 (39.1%)

Age

 Mean (SD)

63.6 (± 16.1)

67 (± 15.1)

62.4 (± 16.5)

58.3 (± 15.8)

 65 years or older n (%)

158 (54.9%)

59 (62.8%)

91 (53.2%)

8 (34.8%)

Mean BMI (SD)

28.3 (± 6.1)

29.2 (± 6.6)

27.8 (± 5.7)

27.8 (± 5.8)

Comorbidities n (%)

 Cardiac insufficiency

14 (4.9%)

4 (4.3%)

8 (4.7%)

2 (8.7%)

 Cerebral ischemia history

28 (10.9%)

13 (13.8%)

13 (7.6%)

2 (8.7%)

 COPD

53 (18.4%)

13 (13.8%)

37 (21.6%)

3 (13%)

 Autoimmune diseases

36 (12.5%)

7 (7.4%)

25 (14.6%)

4 (17.4%)

 Vasculopathy

24 (8.3%)

12 (12.8%)

9 (5.3%)

3 (13%)

 Hepatic cirrhosis

6 (2.1%)

1 (1.1%)

5 (2.9%)

0

 Obesity

91 (31.6%)

35 (37.2%)

51 (29.8%)

5 (21.7%)

 Diabetes

  Compensated disease

63 (21.9%)

24 (25.5%)

36 (21.1%)

3 (13%)

  Decompensated disease

10 (3.5%)

3 (3.2%)

6 (3.5%)

1 (4.3%)

 Chronic kidney diseases

19 (6.6%)

9 (9.6%)

7 (4.1%)

3 (13%)

 Solid cancer

  Localized disease

34 (11.8%)

6 (6.4%)

23 (13.5%)

5 (21.7%)

  Metastatic disease

15 (5.2%)

3 (3.2%)

12 (7.1%)

0

 Hematological malignancies

43 (14.9%)

10 (10.6%)

23 (13.5%)

10 (43.5%)

 AIDS

1 (0.3%)

1 (1.1%)

0

0

 History of peptic ulcer

2 (0.7%)

0

2 (1.2%)

0

 Ischemic heart diseases

36 (12.5%)

15 (16%)

17 (9.9%)

4 (17.4%)

 Dementia

17 (5.9%)

10 (10.6%)

7 (4.1%)

0

 Hemiplegia

3 (1%)

1 (1.1%)

1 (0.6%)

1 (4.3%)

 Hypertension

165 (57.3%)

60 (63.8%)

93 (54.4%)

12 (52.2%)

 Number of comorbidities ≥ 3

113 (39.2%)

44 (46.8%)

60 (35.1%)

9 (39.1%)

 Charlson Comorbidity Index (mean ± SD)

4.1 (± 2.3)

4.2 (± 2.2)

4 (± 2.3)

4.1 (± 2.2)

Vaccination

 Yes

232 (82.3%)

56 (59.6%)

161 (94.2%)

18 (78.3%)

 No

51 (17.7%)

38 (40.4%)

10 (5.8%)

5 (21.7%)

Mean days from symptoms onset to first positive swab (SD)

1.3 (1.4)

1.7 (1.7)

1.2 (1.2)

1.1 (1.1)

Mean days from symptoms onset to treatment (SD)

3.3 (1.9)

3.9 (2.4)

3.1 (1.5)

3.5 (2.2)

Baseline clinical severity n (%)

 ASY

47 (16.3%)

39 (41.5%)

3 (1.8%)

5 (21.7%)

 MID

235 (81.6%)

52 (55.3%)

167 (97.6%)

16 (69.6%)

 MOD

6 (2.1%)

3 (3.2%)

1 (0.6%)

2 (8.7%)

IgG anti-SARS-CoV-2-Spike protein at baseline n (%)

 Positive

70 (24.3%)

45 (47.9%)

18 (10.5%)

7 (30.4%)

 Negative

65 (22.6%)

46 (48.9%)

4 (2.3%)

15 (65.2%)

 N/A

153 (53.1%)

3 (3.2%)

149 (87.1%)

1 (4.3%)

Monoclonal antibodies n (%)*

 Bamlanivimab/Etesevimab

42 (35.9%)

40 (42.6%)

2 (8.7%)

 Casirivimab/Imdevimab

22 (18.8%)

17 (18.1%)

5 (21.7%)

 Sotrovimab

53 (45.3%)

37 (39.4%)

16 (69.6%)

 **Total number

117

94

23

Antivirals n (%)*

 Remdesivir

57 (29.1%)

38 (22.2%)

18 (78.3%)

 Molnupiravir

77 (39.8%)

75 (43.9%)

2 (8.7%)

 Nirmatrelvir/Ritonavir

61 (31.1%)

58 (33.9%)

3 (13%)

 **Total number

195

171

23

COVID-19 progression and related hospital admission

 Yes

4 (1.4%)

3 (3.2%)

1 (0.6%)

0

 No

284 (98.6%)

91 (96.8%)

170 (99.4%)

23 (100%)

  1. SD standard deviation; COPD chronic obstructive pulmonary disease; ASY asymptomatic or pre-symptomatic; MID mild; MOD moderate; COVID-19 Coronavirus Disease 2019
  2. *Percentage is calculated on total number of vaccinated patients as indicated appropriately in each column
  3. **Percentage is calculated on total number of prescribed mAbs and antivirals as indicated appropriately in each column